Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
142 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Allergic Asthma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Allergic Asthma - Pipeline Review, H1 2015', provides an overview of the Allergic Asthma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Asthma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Asthma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Allergic Asthma Overview 10 Therapeutics Development 11 Pipeline Products for Allergic Asthma - Overview 11 Pipeline Products for Allergic Asthma - Comparative Analysis 12 Allergic Asthma - Therapeutics under Development by Companies 13 Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 16 Allergic Asthma - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Allergic Asthma - Products under Development by Companies 20 Allergic Asthma - Products under Investigation by Universities/Institutes 22 Allergic Asthma - Companies Involved in Therapeutics Development 23 ALK-Abello A/S 23 Allergopharma Joachim Ganzer KG 24 Array BioPharma Inc. 25 Aslan Pharmaceuticals Pte. Ltd. 26 Asmacure Ltee 27 BioTech Tools s.a. 28 Fountain Biopharma Inc. 29 Genentech, Inc. 30 Infinity Pharmaceuticals, Inc. 31 Kineta, Inc. 32 Marinomed Biotechnologie GmbH 33 NeoPharm Co., Ltd. 34 Novartis AG 35 Nuvo Research Inc. 36 Panacea Biotec Limited 37 Peptinnovate Limited 38 Pharmaxis Limited 39 Portola Pharmaceuticals, Inc. 40 Protectimmun GmbH 41 Pulmatrix, Inc. 42 Stallergenes S.A. 43 sterna biologicals Gmbh & Co KG 44 Verona Pharma Plc 45 Allergic Asthma - Therapeutics Assessment 46 Assessment by Monotherapy Products 46 Assessment by Combination Products 47 Assessment by Target 48 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (fluticasone propionate + salmeterol xinafoate) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Acaroid - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AcTMP-1 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 allergenic pollen extract of timothy - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Arabinogalactan - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 ARRY-502 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 ASLAN-004 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ASM-024 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 ASM-8 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 dalazatide - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 duvelisib - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 E-3.56 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 FB-825 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 fevipiprant - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 hdm-ASIT - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Lactococcus lactis G121 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 ligelizumab - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 MAM-06301 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 MK-8237 - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 omalizumab biosimilar - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 omalizumab biosimilar - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 PIN-201601 - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 PRT-2607 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 quilizumab - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 RPL-554 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 S-524101 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 SB-010 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 SG-100 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Small Molecule for Allergic Asthma - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Small Molecule for Allergic Asthma - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Small Molecules for Allergic Asthma - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Small Molecules to Inhibit C-Rel for Central Nervous System, Immunology, Musculoskeletal, Oncology, Respiratory and Metabolic Disorders - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Synthetic Peptide for Gastrointestinal, Respiratory and CNS Disorders - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 timothy grass pollen allergen extract - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 WF-10 - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 WF-10 liposomal - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Allergic Asthma - Recent Pipeline Updates 109 Allergic Asthma - Dormant Projects 131 Allergic Asthma - Discontinued Products 134 Allergic Asthma - Product Development Milestones 135 Featured News & Press Releases 135 Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 135 May 16, 2013: Asmacure Announces Presentation Of Four Posters On ASM-024 At ATS 2013 International Conference 136 May 14, 2013: Nuvo Research Secures US Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10 137 Apr 15, 2013: Asmacure Doses First Subjects With ASM-024 Dry Powder For Inhalation 137 Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 138 Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 139 Apr 17, 2012: Pharmaxis Completes Phase II Clinical Study With ASM8 In Asthma Patients 139 Appendix 141 Methodology 141 Coverage 141 Secondary Research 141 Primary Research 141 Expert Panel Validation 141 Contact Us 141 Disclaimer 142
List of Tables Number of Products under Development for Allergic Asthma, H1 2015 11 Number of Products under Development for Allergic Asthma - Comparative Analysis, H1 2015 12 Number of Products under Development by Companies, H1 2015 14 Number of Products under Development by Companies, H1 2015 (Contd..1) 15 Number of Products under Investigation by Universities/Institutes, H1 2015 16 Comparative Analysis by Late Stage Development, H1 2015 17 Comparative Analysis by Clinical Stage Development, H1 2015 18 Comparative Analysis by Early Stage Development, H1 2015 19 Products under Development by Companies, H1 2015 20 Products under Development by Companies, H1 2015 (Contd..1) 21 Products under Investigation by Universities/Institutes, H1 2015 22 Allergic Asthma - Pipeline by ALK-Abello A/S, H1 2015 23 Allergic Asthma - Pipeline by Allergopharma Joachim Ganzer KG, H1 2015 24 Allergic Asthma - Pipeline by Array BioPharma Inc., H1 2015 25 Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 26 Allergic Asthma - Pipeline by Asmacure Ltee, H1 2015 27 Allergic Asthma - Pipeline by BioTech Tools s.a., H1 2015 28 Allergic Asthma - Pipeline by Fountain Biopharma Inc., H1 2015 29 Allergic Asthma - Pipeline by Genentech, Inc., H1 2015 30 Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 31 Allergic Asthma - Pipeline by Kineta, Inc., H1 2015 32 Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H1 2015 33 Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H1 2015 34 Allergic Asthma - Pipeline by Novartis AG, H1 2015 35 Allergic Asthma - Pipeline by Nuvo Research Inc., H1 2015 36 Allergic Asthma - Pipeline by Panacea Biotec Limited, H1 2015 37 Allergic Asthma - Pipeline by Peptinnovate Limited, H1 2015 38 Allergic Asthma - Pipeline by Pharmaxis Limited, H1 2015 39 Allergic Asthma - Pipeline by Portola Pharmaceuticals, Inc., H1 2015 40 Allergic Asthma - Pipeline by Protectimmun GmbH, H1 2015 41 Allergic Asthma - Pipeline by Pulmatrix, Inc., H1 2015 42 Allergic Asthma - Pipeline by Stallergenes S.A., H1 2015 43 Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H1 2015 44 Allergic Asthma - Pipeline by Verona Pharma Plc, H1 2015 45 Assessment by Monotherapy Products, H1 2015 46 Assessment by Combination Products, H1 2015 47 Number of Products by Stage and Target, H1 2015 49 Number of Products by Stage and Mechanism of Action, H1 2015 51 Number of Products by Stage and Route of Administration, H1 2015 53 Number of Products by Stage and Molecule Type, H1 2015 55 Allergic Asthma Therapeutics - Recent Pipeline Updates, H1 2015 109 Allergic Asthma - Dormant Projects, H1 2015 131 Allergic Asthma - Dormant Projects (Contd..1), H1 2015 132 Allergic Asthma - Dormant Projects (Contd..2), H1 2015 133 Allergic Asthma - Discontinued Products, H1 2015 134
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
